| Median OS (95% CI) | HR (95% CI) | p |
---|---|---|---|
Metastatic sites | Â | Â | 0.004 |
   1 | NR | 1 |  |
   >1 | 13.8 (10.4-17.3) | 3.55 (1.50-8.36) |  |
Time between diagnosis/surgery and Sunitinib initiation | Â | Â | 0.001 |
   <= 12 months | 11.6 (8.2-14.9) | 1 |  |
   >12 months | NR | 0.36 (0.19-0.66) |  |
Performance Status | Â | Â | 0.023 |
   <= 1 | 17.4 (10.2-24.6) | 1 |  |
   >1 | 7.6 (0-18.5) | 2.32 (1.12-4.80) |  |
Hb | Â | Â | 0.035 |
   <13 for Males, <11.5 for Females | 14.3 (11.3-17.3) | 1 |  |
   >= 13 for Males, >= 11.5 for Females | NR | 0.51 (0.28-0.95) |  |
Ca | Â | Â | 0.538 |
   <10 | 17.4 (8.3-26.6) | 1 |  |
   >= 10 | 15.1 (8.4-21.7) | 1.29 (0.57-2.90) |  |
LDH | Â | Â | 0.063 |
   Normal | NR | 1 |  |
   Abnormal | 13.8 (8.7-18.9) | 1.78 (0.97-3.26) |  |
ALP | Â | Â | 0.004 |
   Normal | 22.3 | 1 |  |
   Abnormal | 10.7 (6.5-15) | 2.46 (1.34-4.50) |  |
Nephrectomy | Â | Â | 0.001 |
   No | 8.9 (3.8-14.2) | 1 |  |
   Yes | 22.3 | 0.36 (0.19-0.65) |  |